<?xml version="1.0" encoding="UTF-8"?>
<p id="para440">In an analysis by transplantation eligibility status, which was pre-specified in the statistical plan, median progression-free survival was 57 months (95% CI 50–not reached) in the lenalidomide group and 30 months (25–32) in the observation group in transplantation-eligible patients (HR 0·48 [95% CI 0·40–0·58]; p&lt;0·0001; 
 <xref rid="fig4" ref-type="fig">figure 4B</xref>), and in transplantation-ineligible patients, median progression-free survival was 26 months (95% CI 22–31) with lenalidomide and 11 months (5–23) with observation (HR 0·44 [95% CI 0·37–0·53]; p&lt;0·0001; 
 <xref rid="fig4" ref-type="fig">figure 4C</xref>).
</p>
